Integral Health Asset Management LLC Purchases New Position in Oscar Health, Inc. (NYSE:OSCR)

Integral Health Asset Management LLC purchased a new stake in Oscar Health, Inc. (NYSE:OSCR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 700,000 shares of the company’s stock, valued at approximately $9,408,000. Integral Health Asset Management LLC owned about 0.28% of Oscar Health as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in shares of Oscar Health by 348.7% during the 4th quarter. JPMorgan Chase & Co. now owns 10,360,529 shares of the company’s stock worth $139,246,000 after purchasing an additional 8,051,379 shares in the last quarter. BIT Capital GmbH grew its position in shares of Oscar Health by 5,711.6% during the 4th quarter. BIT Capital GmbH now owns 4,473,853 shares of the company’s stock worth $60,129,000 after purchasing an additional 4,396,872 shares in the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Oscar Health by 50.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 11,835,000 shares of the company’s stock worth $159,062,000 after purchasing an additional 3,983,325 shares in the last quarter. Hennessy Advisors Inc. grew its position in shares of Oscar Health by 550.3% during the 4th quarter. Hennessy Advisors Inc. now owns 4,188,400 shares of the company’s stock worth $56,292,000 after purchasing an additional 3,544,300 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC grew its position in shares of Oscar Health by 51.4% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 6,335,862 shares of the company’s stock worth $85,154,000 after purchasing an additional 2,151,256 shares in the last quarter. Institutional investors and hedge funds own 75.70% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company lowered shares of Oscar Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $20.00 to $16.00 in a research report on Thursday, March 13th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Oscar Health currently has a consensus rating of “Hold” and a consensus target price of $20.08.

Oscar Health Trading Up 0.3%

NYSE:OSCR opened at $17.11 on Monday. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $4.29 billion, a price-to-earnings ratio of -855.07 and a beta of 1.75. The firm has a fifty day simple moving average of $13.34 and a two-hundred day simple moving average of $14.61. Oscar Health, Inc. has a 12 month low of $11.20 and a 12 month high of $23.79.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.09. Oscar Health had a net margin of 0.28% and a return on equity of 2.28%. The firm had revenue of $3 billion during the quarter, compared to analysts’ expectations of $2.87 billion. During the same period last year, the company earned $0.62 earnings per share. The business’s revenue was up 42.2% on a year-over-year basis. Analysts expect that Oscar Health, Inc. will post 0.69 EPS for the current fiscal year.

Oscar Health Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.